Ethyl 4-[[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazole-2-carbonyl]sulfamoyl]benzoate | 1404117-68-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: Ethyl 4-[[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazole-2-carbonyl]sulfamoyl]benzoate
• 英文别名: ethyl 4-[[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazole-2-carbonyl]sulfamoyl]benzoate
• CAS: 1404117-68-5
• 化学式: C₂₅H₂₂ClN₃O₅S
• 分子量: 511.986
• InChiKey: KDCHYULBFFKESU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Ethyl 4-[[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazole-2-carbonyl]sulfamoyl]benzoate 在 lithium hydroxide monohydrate 、 五氯化磷 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 氯苯 为溶剂， 生成 4-[[C-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]-N-methylcarbonimidoyl]sulfamoyl]benzoic acid
  参考文献：
  名称：

  JD-5006 and JD-5037: Peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities

  摘要：

  Analogs of SLV-319 (Ibipinibant), a CB1 receptor inverse agonist, were synthesized with functionality intended to limit brain exposure while maintaining the receptor affinity and selectivity of the parent compound. Structure activity relationships of this series, and pharmacology of two lead compounds, 16 (JD-5006) and 23 (JD-5037) showing little brain presence as indicated by tissue distribution and receptor occupancy studies, are described. Effects with one of these compounds on plasma triglyceride levels, liver weight and enzymes, glucose tolerance and insulin sensitivity support the approach that blockade of peripheral CB1 receptors is sufficient to produce many of the beneficial metabolic effects of globally active CB1 blockers. Thus, PR CB1 inverse agonists may indeed represent a safer alternative to highly brain-penetrant agents for the treatment of metabolic disorders, including diabetes, liver diseases, dyslipidemias, and obesity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.004
• 作为产物：
  描述：

  、 3-(4-氯苯基)-4- 苯基-4,5-二氢-1H-吡唑 以 甲苯 为溶剂， 以84 %的产率得到Ethyl 4-[[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazole-2-carbonyl]sulfamoyl]benzoate
  参考文献：
  名称：

  [EN] CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF
  [FR] ANTAGONISTES/AGONISTES INVERSES DU RÉCEPTEUR CANNABINOÏDE 1 ET LEURS UTILISATIONS

  摘要：

  本文公开了适用于治疗疾病的化合物，例如糖尿病疾病、血脂异常疾病、心血管疾病、炎症疾病、肝脏疾病、癌症、肥胖症或其并发症。还公开了含有一种或多种化合物的组合物以及化合物在治疗受试者疾病中的用途。

  公开号：

  WO2023196556A1